NextCell Pharma AB (NXTCL) Stock Statistics & Valuation Metrics

NextCell Pharma AB has a market cap or net worth of kr76.86M. The enterprise value is ―.

NextCell Pharma AB has 111,392,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

NextCell Pharma AB’s return on equity (ROE) is -0.53 and return on invested capital (ROIC) is -50.31%.

The current PE Ratio of NextCell Pharma AB is ―. NextCell Pharma AB’s PEG ratio is 0.13.

In the last 12 months, NextCell Pharma AB had revenue of 10.94M and earned -35.14M in profits. Earnings per share was -0.46.

In the last 12 months, operating cash flow was -38.86M and capital expenditures -4.18M, giving a free cash flow of -43.05M billion.

NextCell Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―

NextCell Pharma AB upcoming earnings date is Jan 22, 2026, TBA (Confirmed).

NextCell Pharma AB as a current ratio of 10.02, with Debt / Equity ratio of 0.00%

In the past 12 months, NextCell Pharma AB has paid 0.00 in taxes.

NextCell Pharma AB EV to EBITDA ratio is -1.58, with an EV/FCF ratio of -1.20.

NextCell Pharma AB has kr38.72M in cash and marketable securities with kr0.00 in debt, giving a net cash position of kr38.72M billion.

Gross margin is -70.33%, with operating margin of -327.98%, and net profit margin of -321.31%.

The average price target for NextCell Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―